Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs: JACC State-of-the-Art Review.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8301365 Publication Model: Print Cited Medium: Internet ISSN: 1558-3597 (Electronic) Linking ISSN: 07351097 NLM ISO Abbreviation: J Am Coll Cardiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [New York, N.Y.] : Elsevier Biomedical, [c1983-
    • Subject Terms:
      Drug Users* ; Endocarditis*/diagnosis ; Endocarditis*/drug therapy ; Endocarditis*/etiology ; Endocarditis, Bacterial*/diagnosis ; Endocarditis, Bacterial*/drug therapy ; Endocarditis, Bacterial*/etiology ; Substance Abuse, Intravenous*/complications ; Substance Abuse, Intravenous*/epidemiology; Humans ; Pharmaceutical Preparations ; Reinfection ; Retrospective Studies
    • Abstract:
      The incidence of injection drug use-associated infective endocarditis has been increasing rapidly over the last decade. Patients with drug use-associated infective endocarditis present an increasingly common clinical challenge with poor long-term outcomes and high reinfection and readmission rates. Their care raises issues unique to this population, including antibiotic selection and administration, indications for and ethical issues surrounding surgical intervention, and importantly management of the underlying substance use disorder to minimize the risk of reinfection. Successful treatment of these patients requires a broad understanding of these concerns. A multidisciplinary, collaborative approach providing a holistic approach to treating both the acute infection along with effectively addressing substance use disorder is needed to improve short-term and longer-term outcomes.
      Competing Interests: Funding Support and Author Disclosures Dr Bearnot is supported by the National Institutes of Health/National Institute on Drug Abuse under grant K12DA043490. Dr Rosenfield has served as a consultant and/or Scientific Advisory Board member for Althea Medical, Angiodynamics, Boston Scientific, Contego, InspireMD, Magneto, Mayo Clinic, Neptune Medical, Phillips, Summa Therapeutics, Surmodics, Thrombolex, Terumo, and Truvic; holds equity in Accolade, Access Vascular, Aerami, Althea Medical, Contego, Cruzar Systems, Embolitech, Endospan, InspireMD, JanaCare, Magneto, Orchestra, PQ Bypass, Prosomnus, Shockwave, Summa Therapeutics, Thrombolex, Truvic, and Valcare; and is a Board Member for National PERT Consortium. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
      (Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
    • Grant Information:
      K12 DA043490 United States DA NIDA NIH HHS
    • Contributed Indexing:
      Keywords: cardiac surgery; infective endocarditis; medications for opioid use disorder; opioid use disorder; people who inject drugs; percutaneous mechanical aspiration; substance use disorder; tricuspid valve endocarditis
    • Accession Number:
      0 (Pharmaceutical Preparations)
    • Publication Date:
      Date Created: 20220519 Date Completed: 20220523 Latest Revision: 20220614
    • Publication Date:
      20240105
    • Accession Number:
      10.1016/j.jacc.2022.03.349
    • Accession Number:
      35589166